{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:27:25Z","timestamp":1790839645518,"version":"4.1.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T00:00:00Z","timestamp":1582156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UC Davis Paul Calabresi Career Development Award for Clinical Oncology"},{"name":"National Cancer Institute\/National Institutes of Health","award":["#5K12-CA138464"],"award-info":[{"award-number":["#5K12-CA138464"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.blre.2020.100672","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T13:50:04Z","timestamp":1582293004000},"page":"100672","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":199,"special_numbering":"C","title":["Targeting MCL-1 in hematologic malignancies: Rationale and progress"],"prefix":"10.1016","volume":"44","author":[{"given":"Andrew H.","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Seth","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Caenepeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zach","family":"McIver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Mezzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong Khanh","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.blre.2020.100672_bb0005","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1111\/febs.13683","article-title":"Bcl-2 proteins in development, health, and disease of the hematopoietic system","volume":"283","author":"Kollek","year":"2016","journal-title":"FEBS J"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrm3722","article-title":"Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy","volume":"15","author":"Czabotar","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0015","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/sj.cdd.4401952","article-title":"Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis","volume":"13","author":"Zhuang","year":"2006","journal-title":"Cell Death Differ"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0020","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/cdd.2017.30","article-title":"Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo","volume":"24","author":"Carrington","year":"2017","journal-title":"Cell Death Differ"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2004.12.030","article-title":"Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function","volume":"17","author":"Chen","year":"2005","journal-title":"Mol Cell"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0030","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1084\/jem.20150983","article-title":"BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice","volume":"213","author":"Hamouda","year":"2016","journal-title":"J Exp Med"},{"key":"10.1016\/j.blre.2020.100672_bb0035","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and regulation of pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"2018","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.237","article-title":"MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL","volume":"7","author":"Vikstrom","year":"2016","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0045","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1182\/blood-2006-03-013771","article-title":"The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages","volume":"109","author":"Dzhagalov","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0050","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1101\/gad.215871.113","article-title":"Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure","volume":"27","author":"Thomas","year":"2013","journal-title":"Genes Dev"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0055","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1101\/gad.215855.113","article-title":"Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction","volume":"27","author":"Wang","year":"2013","journal-title":"Genes Dev"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0060","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/hep.23188","article-title":"The liver's dance with death: two Bcl-2 guardian proteins from the abyss","volume":"50","author":"Cazanave","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0065","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/hep.23126","article-title":"Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver","volume":"50","author":"Hikita","year":"2009","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0070","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/cdd.2017.125","article-title":"The combination of reduced MCL-1 and standard chemotherapeutics is tolerable in mice","volume":"24","author":"Brinkmann","year":"2017","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2020.100672_bb0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pharmthera.2014.08.003","article-title":"Small molecule Mcl-1 inhibitors for the treatment of cancer","volume":"145","author":"Belmar","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"14","key":"10.1016\/j.blre.2020.100672_bb0080","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2016-03-704908","article-title":"Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1","volume":"128","author":"Gong","year":"2016","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0085","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1038\/s41467-018-07551-w","article-title":"Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia","volume":"9","author":"Tron","year":"2018","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0090","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41375-018-0223-9","article-title":"Targeting Bcl-2 for the treatment of multiple myeloma","volume":"32","author":"Touzeau","year":"2018","journal-title":"Leukemia"},{"issue":"7626","key":"10.1016\/j.blre.2020.100672_bb0095","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.blre.2020.100672_bb0100","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1101\/gad.182980.111","article-title":"Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia","volume":"26","author":"Glaser","year":"2012","journal-title":"Genes Dev"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0105","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1101\/gad.232009.113","article-title":"Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53","volume":"28","author":"Kelly","year":"2014","journal-title":"Genes Dev"},{"key":"10.1016\/j.blre.2020.100672_bb0110","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2020.100672_bb0115","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1593\/neo.12598","article-title":"Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1","volume":"14","author":"Trivigno","year":"2012","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0120","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bcp.2014.07.029","article-title":"MCL-1 dependency of cisplatin-resistant cancer cells","volume":"92","author":"Michels","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"7336","key":"10.1016\/j.blre.2020.100672_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature09779","article-title":"Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7","volume":"471","author":"Wertz","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1541-7786.MCR-16-0280-T","article-title":"Key survival factor, Mcl-1, correlates with sensitivity to combined Bcl-2\/Bcl-xL blockade","volume":"15","author":"Williams","year":"2017","journal-title":"Mol Cancer Res"},{"issue":"10","key":"10.1016\/j.blre.2020.100672_bb0135","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4161\/cc.3.10.1196","article-title":"Mcl-1 regulation and its role in multiple myeloma","volume":"3","author":"Le Gouill","year":"2004","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0140","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbrc.2011.09.063","article-title":"Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1","volume":"414","author":"Zhang","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.blre.2020.100672_bb0145","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1007\/s10495-016-1238-1","article-title":"MicroRNA-30 inhibits antiapoptotic factor Mcl-1 in mouse and human hematopoietic cells after radiation exposure","volume":"21","author":"Li","year":"2016","journal-title":"Apoptosis"},{"issue":"10","key":"10.1016\/j.blre.2020.100672_bb0150","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1158\/1078-0432.CCR-14-1437","article-title":"miR-137 and miR-197 induce apoptosis and suppress tumorigenicity by targeting MCL-1 in multiple myeloma","volume":"21","author":"Yang","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.blre.2020.100672_bb0155","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Thomas","year":"2010","journal-title":"FEBS Lett"},{"issue":"11","key":"10.1016\/j.blre.2020.100672_bb0160","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1128\/MCB.00620-06","article-title":"Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization","volume":"27","author":"Ding","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.blre.2020.100672_bb0165","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/cells3020418","article-title":"Mcl-1 ubiquitination: unique regulation of an essential survival protein","volume":"3","author":"Mojsa","year":"2014","journal-title":"Cells"},{"issue":"7277","key":"10.1016\/j.blre.2020.100672_bb0170","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature08646","article-title":"Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival","volume":"463","author":"Schwickart","year":"2010","journal-title":"Nature"},{"issue":"47","key":"10.1016\/j.blre.2020.100672_bb0175","doi-asserted-by":"crossref","first-page":"7863","DOI":"10.1038\/sj.onc.1208069","article-title":"Cleavage of Mcl-1 by caspases impaired its ability to counteract Bim-induced apoptosis","volume":"23","author":"Herrant","year":"2004","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0180","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2141.2004.04949.x","article-title":"Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells","volume":"125","author":"Clohessy","year":"2004","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100672_bb0185","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.celrep.2016.02.039","article-title":"Loss of a single Mcl-1 allele inhibits MYC-driven lymphomagenesis by sensitizing pro-B cells to apoptosis","volume":"14","author":"Grabow","year":"2016","journal-title":"Cell Rep"},{"issue":"10","key":"10.1016\/j.blre.2020.100672_bb0190","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1517\/13543784.2011.609167","article-title":"Targeting Mcl-1 for the therapy of cancer","volume":"20","author":"Quinn","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0195","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/leu.2017.179","article-title":"Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients","volume":"32","author":"Shah","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100672_bb0200","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.leu.2403784","article-title":"Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival","volume":"19","author":"Wuilleme-Toumi","year":"2005","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.blre.2020.100672_bb0205","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2018-03-836718","article-title":"BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment","volume":"132","author":"Gomez-Bougie","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0210","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ni.2527","article-title":"Mcl-1 is essential for the survival of plasma cells","volume":"14","author":"Peperzak","year":"2013","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.blre.2020.100672_bb0215","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V99.6.1885","article-title":"Myeloid cell factor-1 is a critical survival factor for multiple myeloma","volume":"99","author":"Zhang","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0220","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0225","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/bjc.2013.152","article-title":"An antiapoptotic Bcl-2 family protein index predicts the response of leukaemic cells to the pan-Bcl-2 inhibitor S1","volume":"108","author":"Zhang","year":"2013","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.blre.2020.100672_bb0230","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1172\/JCI39964","article-title":"Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia","volume":"120","author":"Xiang","year":"2010","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0235","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.blre.2020.100672_bb0240","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.25000","article-title":"Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","volume":"93","author":"DiNardo","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2020.100672_bb0250","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.561","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6","author":"Leverson","year":"2015","journal-title":"Cell Death Dis"},{"issue":"21","key":"10.1016\/j.blre.2020.100672_bb0255","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1016\/j.bmc.2013.08.017","article-title":"Hydroxyquinoline-derived compounds and analoguing of selective Mcl-1 inhibitors using a functional biomarker","volume":"21","author":"Richard","year":"2013","journal-title":"Bioorg Med Chem"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0290","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0295","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0300","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0305","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","author":"Moujalled","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0310","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","author":"Caenepeel","year":"2018","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.blre.2020.100672_bb0315","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.leukres.2009.05.007","article-title":"Non-Hodgkin lymphoma (NHL) subtypes defined by common translocations: utility of fluorescence in situ hybridization (FISH) in a case-control study","volume":"34","author":"Chang","year":"2010","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.blre.2020.100672_bb0320","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"20","key":"10.1016\/j.blre.2020.100672_bb0325","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood-2016-11-747022","article-title":"Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact","volume":"129","author":"Ennishi","year":"2017","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.blre.2020.100672_bb0330","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1038\/sj.onc.1207648","article-title":"Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage","volume":"23","author":"Michels","year":"2004","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0335","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.humpath.2004.04.018","article-title":"MCL-1 expression in B-cell non-Hodgkin's lymphomas","volume":"35","author":"Cho-Vega","year":"2004","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0340","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1046\/j.1365-2141.2002.03253.x","article-title":"High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma","volume":"116","author":"Kuramoto","year":"2002","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0345","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood-2017-04-737320","article-title":"How I treat double-hit lymphoma","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0350","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/s41379-018-0067-x","article-title":"MYC\/BCL2\/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC\/BCL2 and MYC\/BCL6 double hit lymphomas","volume":"31","author":"Huang","year":"2018","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0355","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1186\/s12885-018-5018-x","article-title":"Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms","volume":"18","author":"Nguyen","year":"2018","journal-title":"BMC Cancer"},{"issue":"20","key":"10.1016\/j.blre.2020.100672_bb0360","doi-asserted-by":"crossref","first-page":"4259","DOI":"10.1021\/jm030190z","article-title":"Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte\/leukemia-2 proteins","volume":"46","author":"Kitada","year":"2003","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.blre.2020.100672_bb0365","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1158\/1078-0432.CCR-04-0551","article-title":"In vitro effects of the BH3 mimetic, (\u2212)-gossypol, on head and neck squamous cell carcinoma cells","volume":"10","author":"Oliver","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2020.100672_bb0370","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ejmech.2018.01.076","article-title":"Small-molecule Mcl-1 inhibitors: emerging anti-tumor agents","volume":"146","author":"Wan","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.blre.2020.100672_bb0375","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1476-4598-7-20","article-title":"Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in follicular small cleaved cell lymphoma model","volume":"7","author":"Arnold","year":"2008","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.blre.2020.100672_bb0380","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/35055095","article-title":"Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3","volume":"3","author":"Tzung","year":"2001","journal-title":"Nat Cell Biol"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0385","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.cdd.4401937","article-title":"Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins","volume":"13","author":"Zhai","year":"2006","journal-title":"Cell Death Differ"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0390","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1002\/prot.23083","article-title":"Molecular dynamics study of small molecule inhibitors of the Bcl-2 family","volume":"79","author":"Acoca","year":"2011","journal-title":"Proteins"},{"issue":"21","key":"10.1016\/j.blre.2020.100672_bb0395","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1021\/jm060460o","article-title":"Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins","volume":"49","author":"Wang","year":"2006","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.blre.2020.100672_bb0400","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/1078-0432.CCR-06-1574","article-title":"Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1","volume":"13","author":"Mohammad","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0405","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if Mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0410","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41418-019-0391-9","article-title":"BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics","volume":"27","author":"Villalobos-Ortiz","year":"2020","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2020.100672_bb0415","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.2147\/OTT.S146228","article-title":"MCL-1 inhibition in cancer treatment","volume":"11","author":"Xiang","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.blre.2020.100672_bb0420","series-title":"Presented at: American Association for Cancer Research, April 1\u20135, 2017","article-title":"Preclinical evaluation of AMG 176, a novel, potent and selective Mcl-1 inhibitor with robust anti-tumor activity in Mcl-1 dependent cancer models","author":"Caenepeel","year":"2017"},{"key":"10.1016\/j.blre.2020.100672_bb0425","series-title":"Oncology Pipeline","year":"2019"},{"key":"10.1016\/j.blre.2020.100672_bb0430","series-title":"Presented at: American Association for Cancer Research 2017 Annual Meeting","article-title":"AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers [abstract]","author":"Hird","year":"2017"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0435","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.stemcr.2018.01.005","article-title":"A non-apoptotic function of MCL-1 in promoting pluripotency and modulating mitochondrial dynamics in stem cells","volume":"10","author":"Rasmussen","year":"2018","journal-title":"Stem Cell Rep"},{"issue":"15","key":"10.1016\/j.blre.2020.100672_bb0440","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1242\/dev.090910","article-title":"Mcl1 regulates the terminal mitosis of neural precursor cells in the mammalian brain through p27Kip1","volume":"140","author":"Hasan","year":"2013","journal-title":"Development"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0445","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.chembiol.2012.07.018","article-title":"A competitive stapled peptide screen identifies a selective small molecule that overcomes MCL-1-dependent leukemia cell survival","volume":"19","author":"Cohen","year":"2012","journal-title":"Chem Biol"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0450","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1158\/1535-7163.MCT-12-0767","article-title":"A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo","volume":"13","author":"Abulwerdi","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0455","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cmdc.201500497","article-title":"Small-molecule and peptide inhibitors of the pro-survival protein Mcl-1","volume":"11","author":"Beekman","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.blre.2020.100672_bb0460","first-page":"350(1)","article-title":"Fragment-based design, synthesis, and biological evaluation of 1-substituted-indole-2-carboxylic acids as selective Mcl-1 inhibitors","author":"Wang","year":"2017","journal-title":"Arch Pharm (Weinheim)"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0465","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1021\/jm901469p","article-title":"Structural insights into the design of small molecule inhibitors that selectively antagonize Mcl-1","volume":"53","author":"Bernardo","year":"2010","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0470","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1021\/jm501258m","article-title":"Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity","volume":"58","author":"Bruncko","year":"2015","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0475","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1021\/jm301448p","article-title":"Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design","volume":"56","author":"Friberg","year":"2013","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0480","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1021\/jm500672y","article-title":"First evidence that oligopyridines, alpha-helix foldamers, inhibit Mcl-1 and sensitize ovarian carcinoma cells to Bcl-xL-targeting strategies","volume":"58","author":"Gloaguen","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.blre.2020.100672_bb0485","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2014.11.035","article-title":"Design, synthesis and evaluation of marinopyrrole derivatives as selective inhibitors of Mcl-1 binding to pro-apoptotic Bim and dual Mcl-1\/Bcl-xL inhibitors","volume":"90","author":"Li","year":"2015","journal-title":"Eur J Med Chem"},{"issue":"62","key":"10.1016\/j.blre.2020.100672_bb0490","doi-asserted-by":"crossref","first-page":"8593","DOI":"10.1039\/C4CC01830C","article-title":"From meiogynin A to the synthesis of dual inhibitors of Bcl-xL and Mcl-1 anti-apoptotic proteins","volume":"50","author":"Desrat","year":"2014","journal-title":"Chem Commun (Camb)"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0495","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/cmdc.201300316","article-title":"De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1","volume":"8","author":"Ding","year":"2013","journal-title":"ChemMedChem"},{"issue":"2","key":"10.1016\/j.blre.2020.100672_bb0500","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-018-0165-5","article-title":"Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells","volume":"9","author":"Fiskus","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.blre.2020.100672_bb0505","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2019.02.007","article-title":"Recent advances in the development of Mcl-1 inhibitors for cancer therapy","volume":"198","author":"Hird","year":"2019","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0510","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1021\/acs.jmedchem.8b01991","article-title":"Discovery of potent myeloid cell leukemia-1 (Mcl-1) inhibitors that demonstrate in vivo activity in mouse xenograft models of human cancer","volume":"62","author":"Lee","year":"2019","journal-title":"J Med Chem"},{"issue":"58","key":"10.1016\/j.blre.2020.100672_bb0515","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.18632\/oncotarget.27262","article-title":"Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide","volume":"10","author":"Hadji","year":"2019","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.blre.2020.100672_bb0520","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41418-018-0209-1","article-title":"Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice","volume":"26","author":"Anstee","year":"2019","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.blre.2020.100672_bb0525","first-page":"9(401)","article-title":"Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer","author":"Merino","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.blre.2020.100672_bb0530","series-title":"Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma","year":"2019"},{"issue":"15","key":"10.1016\/j.blre.2020.100672_bb0535","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/blood-2018-06-859405","article-title":"Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use","volume":"132","author":"Brennan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2020.100672_bb0540","series-title":"Amgen Highlights New Data from Kyprolis (carfilzomib) and Oncology Pipeline at IMW 2019","author":"Amgen","year":"2019"},{"key":"10.1016\/j.blre.2020.100672_bb0545","first-page":"16(12)","article-title":"Synergistic AML cell death induction by marine cytotoxin (+)-1(R), 6(S), 1\u2032(R), 6\u2032(S), 11(R), 17(S)-fistularin-3 and Bcl-2 inhibitor venetoclax","author":"Florean","year":"2018","journal-title":"Mar Drugs"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0550","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.4161\/cbt.29186","article-title":"Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression","volume":"15","author":"Doi","year":"2014","journal-title":"Cancer Biol Ther"},{"issue":"14","key":"10.1016\/j.blre.2020.100672_bb0555","doi-asserted-by":"crossref","first-page":"12668","DOI":"10.18632\/oncotarget.3706","article-title":"Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner","volume":"6","author":"Varadarajan","year":"2015","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.blre.2020.100672_bb0560","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1182\/blood-2014-10-605584","article-title":"Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies","volume":"125","author":"Peterson","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0565","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/jcmm.13886","article-title":"Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1","volume":"22","author":"Luedtke","year":"2018","journal-title":"J Cell Mol Med"},{"issue":"15","key":"10.1016\/j.blre.2020.100672_bb0570","doi-asserted-by":"crossref","first-page":"19367","DOI":"10.18632\/oncotarget.8346","article-title":"Necrostatin-1 enhances the resolution of inflammation by specifically inducing neutrophil apoptosis","volume":"7","author":"Jie","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0575","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/cas.12616","article-title":"TM-233, a novel analog of 1\u2032-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK\/STAT and proteasome activities","volume":"106","author":"Sagawa","year":"2015","journal-title":"Cancer Sci"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0580","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3892\/ijo.2014.2313","article-title":"Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia","volume":"44","author":"Shao","year":"2014","journal-title":"Int J Oncol"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0585","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood-2012-08-447441","article-title":"Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription","volume":"122","author":"Thomas","year":"2013","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0590","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2014-03-559385","article-title":"Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma","volume":"124","author":"Venkata","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.blre.2020.100672_bb0595","doi-asserted-by":"crossref","first-page":"10237","DOI":"10.18632\/oncotarget.2529","article-title":"Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1","volume":"5","author":"Wagner","year":"2014","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0600","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3892\/mmr.2015.3534","article-title":"Apoptosis of HL-60 human leukemia cells induced by Asiatic acid through modulation of B-cell lymphoma 2 family proteins and the mitogen-activated protein kinase signaling pathway","volume":"12","author":"Wu","year":"2015","journal-title":"Mol Med Rep"},{"issue":"20","key":"10.1016\/j.blre.2020.100672_bb0605","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.2174\/138161212800672750","article-title":"Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target","volume":"18","author":"Krystof","year":"2012","journal-title":"Curr Pharm Des"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0610","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.leukres.2015.10.010","article-title":"Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia","volume":"39","author":"Zeidner","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2020.100672_bb0615","article-title":"Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway","volume":"24","author":"Lyle","year":"2018","journal-title":"Am J Manag Care"},{"issue":"7","key":"10.1016\/j.blre.2020.100672_bb0620","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood-2005-04-1678","article-title":"Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death","volume":"106","author":"Chen","year":"2005","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0625","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0928","article-title":"MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor","volume":"14","author":"Xiao","year":"2015","journal-title":"Mol Cancer Ther"},{"issue":"19","key":"10.1016\/j.blre.2020.100672_bb0630","doi-asserted-by":"crossref","first-page":"16912","DOI":"10.18632\/oncotarget.4857","article-title":"Cyclin E\/Cdk2-dependent phosphorylation of Mcl-1 determines its stability and cellular sensitivity to BH3 mimetics","volume":"6","author":"Choudhary","year":"2015","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.blre.2020.100672_bb0635","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1038\/leu.2015.31","article-title":"Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia","volume":"29","author":"Flynn","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0640","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-013-2249-z","article-title":"Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias","volume":"72","author":"Gojo","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.blre.2020.100672_bb0645","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.blre.2020.100672_bb0655","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1158\/1078-0432.CCR-18-3275","article-title":"Co-targeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma","volume":"25","author":"Prukova","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.blre.2020.100672_bb0660","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s12885-017-3383-5","article-title":"Potential mechanisms of resistance to venetoclax and strategies to circumvent it","volume":"17","author":"Tahir","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.blre.2020.100672_bb0665","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.525","article-title":"MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K\/AKT\/mTOR activation in lymphoid malignancies","volume":"6","author":"Choudhary","year":"2015","journal-title":"Cell Death Dis"},{"issue":"4","key":"10.1016\/j.blre.2020.100672_bb0670","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Guieze","year":"2019","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.blre.2020.100672_bb0675","doi-asserted-by":"crossref","first-page":"E202","DOI":"10.1002\/ajh.25146","article-title":"Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia","volume":"93","author":"Chyla","year":"2018","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.blre.2020.100672_bb0680","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.blre.2020.100672_bb0685","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov"},{"issue":"16","key":"10.1016\/j.blre.2020.100672_bb0690","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1158\/1078-0432.CCR-17-3004","article-title":"Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas","volume":"24","author":"Pham","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2020.100672_bb0695","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/s41418-018-0183-7","article-title":"BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-XL","volume":"26","author":"Greaves","year":"2019","journal-title":"Cell Death Differ"},{"issue":"2","key":"10.1016\/j.blre.2020.100672_bb0700","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/leu.2017.243","article-title":"Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1","volume":"32","author":"Teh","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2020.100672_bb0705","series-title":"Full Prescribing Information","author":"VENCLEXTA (Venetoclax)","year":"2018"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0710","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2020.100672_bb0715","doi-asserted-by":"crossref","first-page":"17012","DOI":"10.1038\/sigtrans.2017.12","article-title":"Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells","volume":"2","author":"Luedtke","year":"2017","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"10.1016\/j.blre.2020.100672_bb0720","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41419-018-0932-z","article-title":"BH3 mimetics induce apoptosis independent of DRP-1 in melanoma","volume":"9","author":"Mukherjee","year":"2018","journal-title":"Cell Death Dis"},{"issue":"12","key":"10.1016\/j.blre.2020.100672_bb0725","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1158\/2159-8290.CD-18-0277","article-title":"Exploiting MCL1 dependency with combination MEK + MCL1 inhibitors leads to induction of apoptosis and tumor regression in KRAS-mutant non-small cell lung cancer","volume":"8","author":"Nangia","year":"2018","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.blre.2020.100672_bb0730","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1080\/15384047.2016.1192086","article-title":"Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma","volume":"17","author":"Ponder","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"10.1016\/j.blre.2020.100672_bb0735","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","article-title":"Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease","volume":"30","author":"Roberts","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X20300229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:24:23Z","timestamp":1759436663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X20300229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":140,"alternative-id":["S0268960X20300229"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2020.100672","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting MCL-1 in hematologic malignancies: Rationale and progress","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2020.100672","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100672"}}